Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups
No Thumbnail Available
Identifiers
Date
2021-09-21
Authors
Lacerenza, S.
Moura, D.
Pena-Chilet, M.
Hindi, N.
Dopazo, J.
Sanchez-Bustos, P.
Grignani, G.
Martinez-Trufero, J.
Redondo, A.
Valverde, C.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
Abstract
Immunomodulation has emerged as an active therapeutic option in some solid tumors; however, the efficacy of immunotherapy-based regimens is limited in sarcomas or restricted to a few specific subtypes. IMMUNOSARC was a phase Ib/II trial testing the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab) in bone and soft-tissue sarcoma (STS). In this latter cohort, the trial met its primary endpoint, with 48% of patients free of progression at 6 months (m). We present here, part of the correlative studies associated with the STS cohort.
Description
MeSH Terms
B7-H1 Antigen
Nivolumab
Sunitinib
Sarcoma
Immunomodulation
Nivolumab
Sunitinib
Sarcoma
Immunomodulation
DeCS Terms
Sarcoma
Eficacia
Huesos
Sunitinib
Pacientes
Inmunoterapia
Tejidos
Terapéutica
Eficacia
Huesos
Sunitinib
Pacientes
Inmunoterapia
Tejidos
Terapéutica
CIE Terms
Keywords
Humans, Programmed Cell Death 1 Receptor, Immunotherapy, Angiogenesis
Citation
Lacerenza, S., Moura, D., Pena-Chilet, M., Hindi, N., Dopazo, J., Sanchez-Bustos, P., et al. Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups. Ann. Oncol; 2021-09-21; (32); S1118